The stock price of Usana Health Sciences Inc (NYSE: USNA) has surged by 0.99% when compared to previous closing price of $32.45, but the company has seen a 6.15% gain in its stock price over the last five trading sessions. businesswire.com reported 2025-07-02 that SALT LAKE CITY–(BUSINESS WIRE)–USANA Health Sciences, Inc. (NYSE:USNA) today announced that second quarter 2025 results will be released after the close of market on Tuesday, July 22, 2025. Shortly following the issuance of the Company’s earnings release, the Company will post its Management Commentary document on the Company’s Investor Relations website (http://ir.usana.com) under the News/Events section. USANA will hold a conference call to discuss this announcement with analysts and instit.
Is It Worth Investing in Usana Health Sciences Inc (NYSE: USNA) Right Now?
Usana Health Sciences Inc (NYSE: USNA) has a higher price-to-earnings ratio of 17.95x compared to its average ratio. USNA has 36-month beta value of 0.60. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy”, 0 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for USNA is 11.14M, and currently, short sellers hold a 9.26% ratio of that float. The average trading volume of USNA on July 04, 2025 was 193.04K shares.
USNA’s Market Performance
USNA’s stock has seen a 6.15% increase for the week, with a 9.78% rise in the past month and a 20.70% gain in the past quarter. The volatility ratio for the week is 3.28%, and the volatility levels for the past 30 days are at 2.64% for Usana Health Sciences Inc The simple moving average for the last 20 days is 7.07% for USNA stock, with a simple moving average of -0.30% for the last 200 days.
Analysts’ Opinion of USNA
Jefferies, on the other hand, stated in their research note that they expect to see USNA reach a price target of $53, previously predicting the price at $78. The rating they have provided for USNA stocks is “Underperform” according to the report published on July 07th, 2022.
ROTH Capital gave a rating of “Buy” to USNA, setting the target price at $107 in the report published on December 17th of the previous year.
USNA Trading at 10.35% from the 50-Day Moving Average
After a stumble in the market that brought USNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -32.92% of loss for the given period.
Volatility was left at 2.64%, however, over the last 30 days, the volatility rate increased by 3.28%, as shares surge +10.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +35.19% upper at present.
During the last 5 trading sessions, USNA rose by +6.15%, which changed the moving average for the period of 200-days by -14.71% in comparison to the 20-day moving average, which settled at $30.61. In addition, Usana Health Sciences Inc saw -26.92% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at USNA starting from Fleming John Turman, who sold 500 shares at the price of $29.66 back on Jun 09 ’25. After this action, Fleming John Turman now owns 4,200 shares of Usana Health Sciences Inc, valued at $14,829 using the latest closing price.
Noot Walter, the CHIEF OPERATING OFFICER of Usana Health Sciences Inc, sale 6,291 shares at $30.29 during a trade that took place back on May 27 ’25, which means that Noot Walter is holding 0 shares at $190,568 based on the most recent closing price.
Stock Fundamentals for USNA
Current profitability levels for the company are sitting at:
- 0.07% for the present operating margin
- 0.81% for the gross margin
The net margin for Usana Health Sciences Inc stands at 0.04%. The total capital return value is set at 0.09%. Equity return is now at value 6.78%, with 5.07% for asset returns.
Based on Usana Health Sciences Inc (USNA), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at 2.56. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is 89.57.
Currently, EBITDA for the company is 98.86 million with net debt to EBITDA at -1.71. When we switch over and look at the enterprise to sales, we see a ratio of 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.05.
Conclusion
To put it simply, Usana Health Sciences Inc (USNA) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
